SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Sequenom, Inc. , today announced that Dr. Yves Ville has joined the company’s Clinical Advisory Board. Dr. Ville is a prominent obstetrician-gynecologist and currently serves as professor and chairman of the department of obstetrics and fetal medicine at Necker-Enfants-Malades Hospital at the Paris Descartes University.
“I am delighted that Yves has agreed to join our Clinical Advisory Board,” said Dr. Allan Bombard, chief medical officer at Sequenom. “It’s important to have the highest caliber experts available to help guide our numerous clinical development programs. The unparalleled experience of our Clinical Advisory Board will help ensure that Sequenom has the best clinical development plan possible. The addition of Dr. Ville also adds an important international perspective to our Clinical Advisory Board.”
Dr. Ville was appointed Consultant and Senior Lecturer in Obstetrics and Gynecology and Director of the Fetal Medicine Unit at St Georges’ Hospital and Medical School in London in 1996. In 1998 he was made Full Professor and Chairman of the Department of Obstetrics and Gynecology in Poissy Hospital and Paris-Ouest University. In 2008 he became Chairman of the department of Obstetrics and Fetal Medicine at Necker-Enfants-Malades Hospital, Paris Descartes University.
Dr. Ville serves on the council of the National Agency for Biomedicine as well as on the National Screening Committee in Prenatal Ultrasound. He serves as Associate-Dean for International Affairs at Paris-Descartes Medical School. He is the Director of a Master Degree in Prenatal Diagnosis and Fetal Medicine. He serves as Editor-in-Chief of Ultrasound in Obstetrics and Gynecology. He serves as General Secretary of the European Association of Perinatal Medicine, Board Member of the International Society of Ultrasound in Obstetrics and Gynecology. He is a member of the International Academy of Perinatal Medicine.
About Sequenom
Sequenom, Inc. is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company’s clinical development programs and plans are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company’s financial position, its ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company’s ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
CONTACT: Ian Clements, Ph.D., Sr. Director, Corp. Communications of
Sequenom, Inc., +1-858-202-9000; or Investor Relations, Jody Cain of
Lippert/Heilshorn & Associates, +1-310-691-7100, jcain@lhai.com; or Media
Relations, Dan Budwick of Pure Communications, +1-973-271-6085, both for
Sequenom, Inc.
Web site: http://www.sequenom.com/
